From Google’s Demis Hassabis to Elon Musk, leading technology figures are betting on AI to transform medicine and accelerate drug discovery to eliminates cancers and Alzhemier’s. However, scientists warn that identifying potential treatments is a long way from developing safe and effective cures.
BY PC Bureau
November 11: Artificial intelligence could transform medicine so dramatically that diseases such as cancer, Alzheimer’s, heart disease and mental illness may become relics of the past within a decade. That is the extraordinary prediction made by Anthropic CEO Dario Amodei, who believes AI could usher in an era of medical breakthroughs previously considered beyond human reach.
“These will be relics of the past in, I think, less than a decade,” Amodei said, referring to cancer, Alzheimer’s, heart disease and mental illness.
He described the prospect as the beginning of an unprecedented scientific transformation.
“I think if we do this right, we can create an age of miracles where humanity is able to solve problems that have eluded us for millennia,” he said.
Amodei’s prediction reflects growing optimism among leading figures in the artificial intelligence industry that increasingly powerful AI systems could accelerate biological research, drug discovery and the development of treatments for complex diseases like cancer.
But while AI has already made significant contributions to scientific research, the suggestion that it could effectively eliminate some of humanity’s most difficult diseases within ten years remains highly contentious.
READ: A Love Affair That Cost Nvidia $470 B in Market Value in Two Days
Amodei is not alone in making such ambitious predictions. Other prominent technology leaders, including Elon Musk and Google’s AI chief Demis Hassabis, have also argued that AI could fundamentally change healthcare and bring about breakthroughs at a pace previously unimaginable.
.ier’scer and AlzheHassabism has suggested that AI could compress a decade of drug discovery into weeks, potentially bringing humanity closer to what he has described as the ‘end of disease’ and cure killers like can
He has pointed to AlphaFold, Google’s AI system that predicted the structures of more than 200 million proteins, as evidence of how machine learning can accelerate biological research.
AlphaFold represents a major scientific achievement. However, predicting protein structures is not the same as discovering effective treatments or curing complex diseases such as cancer and Alzheimer’s.
Musk has also predicted that AI will eventually make the world’s best medical care accessible to everyone, at a level comparable to the treatment received by the US president.
Yet the optimism of technology executives is not universally shared by those who develop medicines and conduct clinical research.
ANTHROPIC CEO SAYS THAT CANCER, ALZHEIMER’S, MENTAL ILLNESS, HEART DISEASE, ETC WILL ALL BE CURED IN LESS THAN 10 YEARS…
MORE DATA CENTERS. https://t.co/8dQgcLoJGv
— Just a Dude Who Invests (@DudeWhoInvests) November 11, 2026
Experts and drugmaker CEOs aren’t convinced
Jeff Leiden, executive chairman of Vertex Pharmaceuticals, has dismissed some of the more extravagant claims about AI-driven drug discovery as “complete BS”.
He has cited an exercise in which Vertex evaluated around 50 AI companies and their ability to identify promising drug candidates from a pool of approximately 10,000 compounds. According to Leiden, none produced a working drug independently.
Pharmaceutical industry executives argue that identifying a potentially useful molecule is only the first step in developing a medicine.
A candidate drug must undergo extensive laboratory research, testing in animal models where appropriate, and multiple phases of human clinical trials to establish its safety and effectiveness. It must then pass regulatory scrutiny before it can be approved for widespread use.
The entire drug-development process typically takes 10 to 12 years, although timelines vary considerably between medicines.
AI could help researchers identify promising molecules, analyse biological data, predict protein interactions and narrow down potential treatments. But it cannot automatically eliminate the need to establish whether a drug is safe and effective in human beings.
Critics, including cognitive scientist Gary Marcus and cardiologist and digital medicine expert Eric Topol, have also cautioned against assuming that increasingly capable AI systems possess the deep biological and causal understanding needed to deliver revolutionary medical breakthroughs.
As of 2026, AI has contributed to drug discovery and development, but no AI-designed medicine has yet demonstrated the kind of broad clinical success that would substantiate predictions of the imminent elimination of major diseases.
There is also a history of medical breakthroughs being promised on timelines that proved unrealistic.
The 1970s ‘war on cancer’, launched with the hope of rapidly defeating the disease, is often cited as an example of how scientific ambition can outpace medical reality. Despite decades of progress in cancer research, the disease remains a major global health challenge.
AI could undoubtedly shorten parts of the research and drug-development process. It may also help scientists understand diseases that have resisted conventional approaches for generations.
But discovering a promising treatment, demonstrating its safety, proving its effectiveness and making it accessible to millions of patients are very different challenges.
The coming decade could bring remarkable advances in medicine. Whether it will make cancer, Alzheimer’s and other major diseases relics of the past, as Amodei predicts, remains an open question.
